The emergence of mephedrone and also other artificial cathinones has introduced challenges for lawmakers and regulatory companies tasked with controlling the proliferation of latest psychoactive substances. The dynamic character of artificial drug generation, coupled with the ability of chemists to switch molecular structures to evade legal constra